1,038 Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Leuthold Group LLC

Leuthold Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,303 shares of the biopharmaceutical company’s stock after buying an additional 1,038 shares during the quarter. Leuthold Group LLC’s holdings in Regeneron Pharmaceuticals were worth $7,812,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Fulcrum Asset Management LLP acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $519,000. StoneRidge PMG Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $610,000. University of Texas Texas AM Investment Management Co. lifted its holdings in Regeneron Pharmaceuticals by 66.1% in the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 98 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 39 shares during the last quarter. Almanack Investment Partners LLC. lifted its holdings in Regeneron Pharmaceuticals by 9.6% in the 3rd quarter. Almanack Investment Partners LLC. now owns 711 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 62 shares during the last quarter. Finally, Brighton Jones LLC boosted its position in Regeneron Pharmaceuticals by 24.9% during the third quarter. Brighton Jones LLC now owns 5,400 shares of the biopharmaceutical company’s stock worth $4,094,000 after purchasing an additional 1,075 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a “sector perform” rating in a research report on Monday, November 2nd. Evercore boosted their price objective on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. Finally, Leerink Partners raised their target price on shares of Regeneron Pharmaceuticals from $835.00 to $997.00 and gave the company a “market perform” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 7,439 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total value of $7,219,251.94. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,652,693.38. This trade represents a 81.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 7,830 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the sale, the director owned 5,219 shares of the company’s stock, valued at $5,057,680.71. This represents a 60.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 27,028 shares of company stock valued at $25,025,950. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $919.96 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 3.66. The firm has a market capitalization of $94.72 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 1.38 and a beta of 0.10. The company’s fifty day moving average is $806.90 and its two-hundred day moving average is $743.66. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.83 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.